Skip to main content
Vai all'homepage della Commissione europea (si apre in una nuova finestra)
italiano it
CORDIS - Risultati della ricerca dell’UE
CORDIS

Polymeric Cyclodextrin-Based Supramolecular Constructs Photoreleasing Nitric Oxide for Combating Antibiotic Resistance

Descrizione del progetto

Un’arma suprema contro la resistenza agli antibiotici

I batteri multifarmaco resistenti compaiono dall’accumulo di più geni che conferiscono la capacità di resistere a diversi antibiotici. Questi microrganismi rappresentano un grave problema medico, minacciando l’esito di interventi chirurgici e di infezioni semplici. Il progetto SUPREME, finanziato dal programma di azioni Marie Skłodowska-Curie, intende mettere a punto un approccio terapeutico innovativo per contrastare i batteri multifarmaco resistenti utilizzando l’ossido nitrico. Quest’ultimo è coinvolto nelle reazioni immunitarie contro diversi patogeni. Inoltre, inibisce le pompe di efflusso di farmaci responsabili della multifarmaco resistenza. I ricercatori svilupperanno un nanosistema sofisticato che risponde alla luce rilasciando il carico terapeutico, ossia antibiotici e ossido nitrico.

Obiettivo

With more than 13 million people dying per year from infectious diseases Multidrug Resistance (MDR) in bacteria remains the
greatest challenge in public health care. This scenario, associated to the low turnover of new clinically approved antibiotic
drugs makes the development of innovative therapeutic approaches to fight antibiotic resistance desperately needed to
address this devastating societal problem. In this frame, SUPREME aims at the implementation of a novel strategy based
on unprecedented supramolecular platforms based on new cyclodextrin polymers integrating light-activatable nitric oxide (NO)
photodonors (NOPD), alone and in combination with antibiotics currently employed in the clinic. The final goal is to exploit
the double role of NO generated with superb spatiotemporal control thanks to the light triggering, as: i)
bactericidal species not suffering MDR when produced at high doses (micro molar); ii) inhibitor of the efflux pumps mainly responsible
for MDR, when produced at low doses, to revert antibiotic resistance. Highly biocompatible branched polymers containing mixed (alpha, beta and gamma) cyclodextrin units will be used as suitable hosts able to self-assemble into nanoparticles or gels
encapsulating the therapeutic cargo with high efficiency. We will focus on NOPDs activatable exclusively with the
biocompatible visible light and on antibiotics representative of the classes of fluoroquinolones and
tetracyclines, known to display resistance and severe side effects. Full chemico-physical and photochemical characterization
of the systems is planned as well as assessment of their efficacy against planktonic microbial cells and biofilms. The complementary
expertise of the researcher and the supervisor supported by the private and academic teams hosting the fellow during
secondments will create a multidisciplinary environment where all participants will benefit from reciprocal transfer of
knowledge.

Campo scientifico (EuroSciVoc)

Parole chiave

Programma(i)

Argomento(i)

Meccanismo di finanziamento

HORIZON-TMA-MSCA-PF-EF - HORIZON TMA MSCA Postdoctoral Fellowships - European Fellowships

Vedi tutti i progetti finanziati nell’ambito di questo schema di finanziamento

Invito a presentare proposte

(si apre in una nuova finestra) HORIZON-MSCA-2021-PF-01

Vedi tutti i progetti finanziati nell’ambito del bando

Coordinatore

UNIVERSITA DEGLI STUDI DI CATANIA
Contributo netto dell'UE
€ 172 750,08
Indirizzo
PIAZZA UNIVERSITA 2
95131 Catania
Italia
Regione
Isole Sicilia Catania
Tipo di attività
Higher or Secondary Education Establishments
Collegamenti
Costo totale
Nessun dato

Partner (2)